BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36443709)

  • 1. Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation.
    Zhao Q; Wang Y; Yu D; Leng JY; Zhao Y; Chu M; Xu Z; Ding H; Zhou J; Zhang T
    BMC Cancer; 2022 Nov; 22(1):1229. PubMed ID: 36443709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells.
    Chaudhary J; Johnson J; Kim G; Skinner MK
    Endocrinology; 2001 May; 142(5):1727-36. PubMed ID: 11316735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro.
    Weiler S; Ademokun JA; Norton JD
    Mol Cancer; 2015 Feb; 14(1):30. PubMed ID: 25644253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ID2 and ID3 protein expression mirrors granulopoietic maturation and discriminates between acute leukemia subtypes.
    May AM; Frey AV; Bogatyreva L; Benkisser-Petersen M; Hauschke D; Lübbert M; Wäsch R; Werner M; Hasskarl J; Lassmann S
    Histochem Cell Biol; 2014 Apr; 141(4):431-40. PubMed ID: 24292846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet to white blood cell ratio was an independent prognostic predictor in acute myeloid leukemia.
    Zhao S; Pan H; Guo Q; Xie W; Wang J
    Hematology; 2022 Dec; 27(1):426-430. PubMed ID: 35413229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of SPAG1 expression as a prognostic and predictive biomarker in acute myeloid leukemia by integrative bioinformatics and clinical validation.
    Gu Y; Chu MQ; Xu ZJ; Yuan Q; Zhang TJ; Lin J; Zhou JD
    BMC Med Genomics; 2022 Feb; 15(1):38. PubMed ID: 35227274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel 5-gene prognostic signature to improve risk stratification of cytogenetically normal acute myeloid leukemia.
    Deng C; Zeng T; Zhu P; Zhao S; Huang Z; Huang W; Zhang W; Huang X; Fu L
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10015-10025. PubMed ID: 37258721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML.
    Hollink IH; Zwaan CM; Zimmermann M; Arentsen-Peters TC; Pieters R; Cloos J; Kaspers GJ; de Graaf SS; Harbott J; Creutzig U; Reinhardt D; van den Heuvel-Eibrink MM; Thiede C
    Leukemia; 2009 Feb; 23(2):262-70. PubMed ID: 19020547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
    Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrózek K; Bucci D; Carroll AJ; Baer MR; Wetzler M; Carter TH; Powell BL; Kolitz JE; Moore JO; Eisfeld AK; Blachly JS; Blum W; Caligiuri MA; Stone RM; Marcucci G; Croce CM; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18679-84. PubMed ID: 25512507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
    Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
    J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
    Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
    J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
    Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of inhibitor of differentiation/DNA-binding gene family in lung cancer using bioinformatics methods.
    Xu S; Wang Y; Li Y; Zhang L; Wang C; Wu X
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32003423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.